University of Pennsylvania's Perelman School of Medicine: Patients on a Low-Calorie Diet Along With Intensive Behavioral Therapy Lost Nearly Three Times as Much Weight When Taking New Anti-Obesity Medication, Semaglutide, Than When Taking Placebo
February 25, 2021
February 25, 2021
PHILADELPHIA, Pennsylvania, Feb. 25 (TNSJou) -- The University of Pennsylvania's Perelman School of Medicine issued the following news release on Feb. 24, 2021:
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weig . . .
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weig . . .